Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aerovate Therapeutics Inc
(NQ:
AVTE
)
1.870
+0.030 (+1.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aerovate Therapeutics Inc
Aerovate Therapeutics to Explore Strategic Alternatives
July 08, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
June 17, 2024
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
May 21, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
May 13, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
March 27, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
March 25, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
March 06, 2024
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
November 20, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
November 13, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
August 14, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
July 11, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
June 01, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
May 22, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
May 15, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
March 29, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
March 02, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
January 23, 2023
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
November 17, 2022
Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participants
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
November 14, 2022
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
October 18, 2022
Adaptive and efficient trial design may allow for expedited development timeline while maintaining scientific rigor
From
Aerovate Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.